We have been short on $MDT (Medtronics) with the first scale in at $36.20 and more aggressive entry at $38.00. $BSX earnings show weakness in both stents and implantable cardiac devices. Going forward guidance for US is quite a bit lower than expected.

This confirms our thesis and we will stay short on $MDT.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER